1071 related articles for article (PubMed ID: 26211972)
1. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Miller OH; Moran JT; Hall BJ
Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
[TBL] [Abstract][Full Text] [Related]
2. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of ketamine action as an antidepressant.
Zanos P; Gould TD
Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
[TBL] [Abstract][Full Text] [Related]
4. Ketamine: The final frontier or another depressing end?
Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
[TBL] [Abstract][Full Text] [Related]
5. Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.
Widman AJ; McMahon LL
Proc Natl Acad Sci U S A; 2018 Mar; 115(13):E3007-E3016. PubMed ID: 29531088
[TBL] [Abstract][Full Text] [Related]
6. TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats.
Hara H; Suzuki A; Kunugi A; Tajima Y; Yamada R; Kimura H
Pharmacol Biochem Behav; 2021 Dec; 211():173289. PubMed ID: 34655652
[TBL] [Abstract][Full Text] [Related]
7. Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests.
Andreasen JT; Gynther M; Rygaard A; Bøgelund T; Nielsen SD; Clausen RP; Mogensen J; Pickering DS
Neurosci Lett; 2013 Jun; 546():6-10. PubMed ID: 23643996
[TBL] [Abstract][Full Text] [Related]
8. Impact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons.
El Iskandrani KS; Oosterhof CA; El Mansari M; Blier P
J Psychopharmacol; 2015 Jul; 29(7):792-801. PubMed ID: 25759403
[TBL] [Abstract][Full Text] [Related]
9. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine.
Miller OH; Yang L; Wang CC; Hargroder EA; Zhang Y; Delpire E; Hall BJ
Elife; 2014 Oct; 3():e03581. PubMed ID: 25340958
[TBL] [Abstract][Full Text] [Related]
10. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
11. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
12. GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions.
Gerhard DM; Pothula S; Liu RJ; Wu M; Li XY; Girgenti MJ; Taylor SR; Duman CH; Delpire E; Picciotto M; Wohleb ES; Duman RS
J Clin Invest; 2020 Mar; 130(3):1336-1349. PubMed ID: 31743111
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.
Aleksandrova LR; Phillips AG; Wang YT
J Psychiatry Neurosci; 2017 Jun; 42(4):222-229. PubMed ID: 28234212
[TBL] [Abstract][Full Text] [Related]
14. NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism.
Kiselycznyk C; Jury NJ; Halladay LR; Nakazawa K; Mishina M; Sprengel R; Grant SG; Svenningsson P; Holmes A
Behav Brain Res; 2015; 287():89-95. PubMed ID: 25800971
[TBL] [Abstract][Full Text] [Related]
15. Ketamine and other potential glutamate antidepressants.
Dutta A; McKie S; Deakin JFW
Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
[TBL] [Abstract][Full Text] [Related]
16. NMDA antagonist treatment of depression.
Williams NR; Schatzberg AF
Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
[TBL] [Abstract][Full Text] [Related]
17. Ketamine and suicidal ideation in depression: Jumping the gun?
Rajkumar R; Fam J; Yeo EY; Dawe GS
Pharmacol Res; 2015 Sep; 99():23-35. PubMed ID: 25982932
[TBL] [Abstract][Full Text] [Related]
18. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Abdallah CG; Sanacora G; Duman RS; Krystal JH
Annu Rev Med; 2015; 66():509-23. PubMed ID: 25341010
[TBL] [Abstract][Full Text] [Related]
19. Ketamine for Treatment-Resistant Depression: a New Advocate.
Pérez-Esparza R
Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
[TBL] [Abstract][Full Text] [Related]
20. [Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
Encephale; 2014 Feb; 40(1):48-55. PubMed ID: 24434007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
